Mutations dislocate caspase-12 from the endoplasmatic reticulum to the cytosol  by Hoppe, Viviane & Hoppe, Jürgen
FEBS 28842 FEBS Letters 576 (2004) 277–283Mutations dislocate caspase-12 from the endoplasmatic reticulum
to the cytosolViviane Hoppe, J€urgen Hoppe*
Physiological Chemistry, Biozentrum, University of W€urzburg, Am Hubland, 97074 W€urzburg, Germany
Received 30 August 2004; accepted 6 September 2004
Available online 18 September 2004
Edited by Jesus AvilaAbstract Mouse AKR-2B cells express two forms of caspase-
12: the full-length form coding for a protein of 47.8 kDa and a
new splice variant of 40.2 kDa which is devoid of the CARD
domain. In addition, three point mutations were disclosed: I/L-
15, E/D-46 and P/L-105. A major portion of the two protein
variants was found in the cytosol. Immunoﬂuorescence studies
showed an even distribution of caspase-12 within the cell,
indicative for a cytoplasmatic localization. Transfection of
AKR-2B cells with wild-type caspase-12 showed a colocalization
of this protein with the endoplasmic reticulum (ER). Unlike
mouse embryonal ﬁbroblasts (MEF) which contain wild-type
caspase-12, AKR-2B cells were largely resistant against treat-
ment with the endoplasmatic reticulum stressing reagents
brefeldin and tunicamycin. In AKR-2B cells, cytoplasmatic
caspase-12 is bound to high molecular weight complexes of
>1000 kDa [Cell Death Diﬀer. 9 (2001) 125] and serum
depletion leads to cleavage and detachment of caspase-12 from
this high molecular weight complex. Cleavage of caspase-12 and
-3 occurred almost simultaneously reaching a maximum 3–5 h
after serum deprivation at which time also maximum apoptosis is
found. Analysis of caspase-12 cleavage in vitro in comparison
with fragmentation in vivo suggests that during death in AKR-2B
cells induced by starvation, cleavage was brought about by
caspase-3 at positions D24 and D94. Thus, mutated caspase-12
is diﬀerently integrated in signaling pathways of cell death and
has lost its function as initiator caspase upon ER-stress. Instead,
it is turned into a substrate of eﬀector caspases. The implication
of these ﬁndings in the pathological phenotype of ARK-2B mice
is discussed.
 2004 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
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The caspase protease family plays a central role in the im-
plementation of apoptosis in vertebrates [1,2]. Caspases are
activated upon processing of a precursor into 20-kDa (p20)
and 10-kDa (p10) mature fragments forming heterotetramers
[3]. Alternatively, for caspase-9, the formation of dimers is* Corresponding author. Fax: +49-931-888-41-13.
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doi:10.1016/j.febslet.2004.09.012suﬃcient for activation [4]. The caspase family is broadly di-
vided into two groups: initiator caspases (caspase-8, -9, and
-12) and eﬀector caspases (caspase-3, -6, and -7), which can be
activated via sequential processing by other caspase family
members [1,5]. The implication of diﬀerent organelles has been
reviewed in [2].
Caspase-12 has been described to function as an initiator
caspase in response to a toxic insult of the endoplasmic re-
ticulum (ER) [6], such as by treatment with tunicamycin (an
inhibitor of glycosylation), thapsigargin (an inhibitor of the
ER-speciﬁc calcium ATPase), or calcium ionophores [7–11].
Furthermore, caspase-12-deﬁcient cells are resistant to induc-
ers of ER stress, suggesting that caspase-12 is involved in ER
stress-induced apoptosis. Caspase-12-deﬁcient mice show a
reduced sensitivity to tunicamycin-induced renal tubular epi-
thelial cell death and to amyloid-b-induced neuronal cell
death. Based on the latter ﬁnding, caspase-12 was suggested to
play an important role in the pathogenesis of Alzheimer’s
disease and to represent a potential target for its treatment [8].
However, in humans diﬀerent splice variants of caspase 12
are expressed leading to a premature termination. A small
population of black Africans express a full-length caspase-12,
which due to a point mutation is catalytically inactive. De-
tailed studies have excluded the proposed pathogenic role in
the development of Alzheimer’s disease in humans [12,13].
Murine caspase-12, which has a CARD domain and is
speciﬁcally localized on the cytoplasmic side of the ER, is
processed within its intersubunit region at amino acids D318
and D341 [7,10,14,15]. Several possible molecular mechanisms
for the processing of caspase-12 have been postulated: (1)
caspase-12 is initially processed at the N-terminal region after
K158 by calpain activated by ER stress, then activated and
autoprocessed at D318 [7], (2) caspase-12 is released from
TRAF2 complexes by ER stress and is then autoprocessed via
homodimerization [16,17], (3) caspase-12 is processed at D94
by caspase-7 and then autoprocessed at D341 [10]. Thus, the
molecular mechanism by which caspase-12 is activated seems
to vary within diﬀerent model systems. Once activated, cas-
pase-12 can speciﬁcally cleave procaspase-9 in vitro and in vivo
[18,19], which in turn can then activate the eﬀector caspase-3.
Density-arrested AKR-2B ﬁbroblasts die rapidly after serum
deprivation exhibiting typical morphological changes includ-
ing membrane blebbing and chromatin condensation, but no
DNA fragmentation. Furthermore, dead cells are rapidly
lysed. We have shown previously that all caspases are ex-
pressed in AKR-2B cells with the exception of caspase-7.
Caspase-3 is the main executioner caspase during apoptosisblished by Elsevier B.V. All rights reserved.
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[20–26].
We have demonstrated the formation of two diﬀerent-sized
complexes of caspase-3 in response to serum deprivation. The
600- and 250-kDa multimeric apoptosome-like complexes
contain activated caspase-3, but are devoid of apoptosis pro-
tease activating factor-1 (apaf-1) and cytochrome c [25,26].
The proenzyme of caspase-12 was found to be bound to
cytosolic high molecular weight complexes from which it was
released after activation by serum deprivation as well as an-
isomycin treatment [25,26]. Here, we demonstrate that this
activation is not coupled to ER stress. Sequence analyses of
caspase-12 from AKR-2B cells revealed mutations that are
responsible for its diﬀerent subcellular localization. This dif-
ferent localization alters largely its implication and position inFig. 1. Caspase-12 is upregulated in conﬂuent cells. (A) Total RNA
was isolated from conﬂuent (c) or proliferating AKR-2B cells (p) and
equal amounts were used for RT-PCR. GAPDH was used as control.
(B) Lysates were prepared by treatment of the cells with Cytobuster.
Blots were probed with the caspase-12 antibody. Control: staining with
Amido Black (47 kDa protein).
Fig. 2. Amino acid sequence of caspase-12. The amino acid sequence of cas
published murine sequence [28], and the sequences from MEF, AKR-2B fulthe pathway of cell death. Instead of being an initiator caspase,
caspase-12 in AKR-2B cells is rather a substrate for caspase-3.2. Materials and methods
2.1. Materials
The antibody against caspase-12 was from Cell Signaling Technol-
ogy (CST, Frankfurt, Germany), against Grp-78 from Stressgene/
Biomol (Hamburg, Germany) and against the HA-tag from Roche
(Mannheim, Germany), against full-length caspase-3 from BD Bio-
sciences (Heidelberg, Germany). ER-tracker Blue-White DPX was
from Molecular Probes (Mobitec, Hamburg, Germany). Tunicamycin,
brefeldin, thapsigargin, A23187 and ProteoExtract (S-PEK) were from
Calbiochem (Merck Bioscience, Bad Soden, Germany). Cytobuster
was from Novagen (Merck Bioscience, Bad Soden, Germany). Cy3-
labeled goat-anti-rabbit antibody was from Dianova (Hamburg,
Germany). The plasmids pIRES2-EGFP and pECFP-ER were from
Clontech (Heidelberg, Germany).
2.2. Cell culture
Stock cultures of AKR-2B mouse ﬁbroblasts were propagated in
antibiotic-free McCoy-5A medium (Life Technologies, Eggenstein,
Germany) with 5% Hyclone calf serum for less than 3 months to
minimize ﬂuctuations. Cultures were seeded at a density of 5 103
cells/cm2 into plastic dishes (Falcon, Becton Dickinson, Heidelberg,
Germany) and grown for 5 days without medium change. For the
determination of cell numbers, 12 well plates were used. After the
addition of the indicated compounds, cells were detached by trypsi-
nization at the indicated time and the number of viable cells was de-
termined by the Casy I cell counter. MEF cells (mouse embryo
ﬁbroblasts transformed with the tet-repressor) were purchased from
Clontech, kept in DMEM containing 5% Hyclone calf serum and were
propagated similar to AKR-2B cells.
2.3. Gel electrophoresis and immunoblotting
For gel electrophoresis, cell lysates were prepared either by treat-
ment with Cytobuster (Novagen) or fractionated using the subcellular
fractionation kit S-PEK from Calbiochem (Merck Bioscience, Soden,
Germany). Blotting and detection by chemiluminescence were done as
previously described [27]. Loading control was done by staining the
nitrocellulose sheets with Amido Black. Bands representing a
prominant 47 kDa protein are shown in the individual Western blots
(control).
2.4. cDNA cloning
The cDNA coding for the full-length mouse caspase-12 was obtained
by PCR by using the forward primer GCA CGA GCA CAG CCApase-12 was deduced from the cDNA sequence. The alignment of the
l length and splice variant are shown.
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CTG TGC TA (Casp12-Rev) from a Marathon-Ready cDNA library
from mouse 15-day embryo (Clontech, Heidelberg, Germany) using
the Advantage HF 2 polymerase (Clontech). DNA-sequencing con-
ﬁrmed that the obtained DNA did not contain any mutation [28].
cDNAs for caspase-12 from AKR-2B and MEF cells were obtained by
RT-PCR starting from whole RNA by using the primer GAG TCC
TGC ACA GCC ATG G (Casp12g-For2) and the reverse primer
(Casp12-Rev). To exclude mutations caused by PCR, at least four
clones were completely sequenced.
The vector pIRES2-EGFP was modiﬁed to contain the sequence
coding for an HA-tag (SalI and BamHI) at the C-terminal site of an
integrated protein. The full-length caspase-12 cDNA from the Mara-
thon library was cloned by PCR into the BglII/SalI sites of the mod-
iﬁed expression vector pIRES2-EGFP. Cystein 298 was mutated into
alanine by PCR according to the QuikChange protocol from Strata-
gene (Amsterdam, The Netherlands) yielding the plasmid pC12-WT-
P2-HA.
2.5. Transfection and microscopy
18 hours prior to transfection, 4 106 AKR-2B ﬁbroblasts from a
conﬂuent culture were seeded into 14.5 cm plates. Cells were then de-
tached with trypsin and 2 106 cells were resuspended in hypoosmol-Fig. 3. Subcellular localization of caspase-12. (A) Subcellular localization. Th
kit. Equal amounts of protein (15 lg) were analyzed by Western blotting. B
antibody against Grp-78 (ER), an antibody against omi (mitochondria), and
(C) and the membrane/organelle (M) fractions are shown. (B) Immunoﬂuore
plasmid pECFP-ER and stained with the polyclonal antibody for caspase-12;
after transfection. (d–f) AKR-2B cells were transfected with plasmid pC12-W
antibody; left stain with anti-HA antibody, middle ER-tracker, right merge.aric buﬀer (0.3 mM KH2PO4, 0.85 mM K2HPO4, 25 mM myo-inositol
and 100 mOsmol). Transfection with 10 lg of plasmid DNA was done
using an electroporator (Eppendorf, Hamburg, Germany) with 400 V,
100 ls, and two pulses. Transfection eﬃciency was 30–50% as estimated
by the expression of the EGFP or ECFP. Cells were seeded onto cov-
erslips and were analyzed 24 h later. After ﬁxation in 3% paraformal-
dehyde, cells were permeabilized by treatment for 5 min in 0.2% Triton
X-100 in PBS. Non-speciﬁc binding was blocked by incubation with
0.2% gelatine in PBS. Staining with anti-caspase-12 antibody from CST
(10 lg/ml) was done overnight at 4 C. Counterstaining was done with
Cy3-labeled anti-rabbit antibody (1 lg/ml). The coverslips were then
processed as described. Filters A, I3, N1 (Leica, Bensheim, Germany)
or XF114-2 (Omega, Vermont, USA) were used to monitor blue, cyan,
green or red ﬂuorescence, respectively. Photographs were recorded
using a cooled digital camera (Kappa, Gleichen, Germany). No stain-
ing was observed when the primary antibody was omitted. If indicated,
ER-tracker (1lg/ml) was added to living cells for 1 h.
2.6. RT-PCR
5 lg of total RNA, prepared according to Chomczynski and Sacchi
[29] were taken for RT-PCR by using the primers Casp12-For2 and
Casp12-Rev and HotStarTaq polymerase from Qiagen (Hilden,
Germany).e cellular content was fractionated using the S-PEK cell fractionation
lots were probed with the polyclonal antibody against caspase-12, an
an antibody against full-length caspase-3 (cytosol). Only the cytosolic
scence and transfection (a–c) AKR-2B cells were transfected with the
left: caspase-12, middle: ECFP, right: merge. Pictures were taken 24 h
T-P2-HA and subsequently stained with ER-tracker and the anti HA-
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For the expression in Escherichia coli, a cDNA coding for the full-
length mouse caspase-3 was ampliﬁed from a Marathon-Ready cDNA
library from 15-days old mouse embryo (Clontech, Heidelberg. Ger-
many) using the forward primer CGC TAA GAA AAG TGA CCA
TGG AG and the reverse primer ACC CCC AAT CAT TCC TCT
AGT GA. Expression was done as described in [30].
2.8. In vitro translation
Various fragments of caspase-12 were cloned either into the NcoI /
BamHI sites of the vector pET-3d or the NdeI/XhoI sites of the vector
pET-21b with a stop codon before the His-tag. Site-directed muta-
genesis was done according to the QuikChange protocol from Strat-
agene (Amsterdam, The Netherlands). Mutations were veriﬁed by
DNA-sequencing. In vitro translation was done using the Rapid
Translation System from Roche (Mannheim, Germany) according to
the manufacturer’s instructions.
For treatment with caspase-3, 1.5 lg recombinant caspase-3 was
added to 10 ll in vitro translation mixture.A
B
20
40
60
80
100
0.0 1 10
20
40
60
80
100
 concentration (µM)
A 23187 20
40
60
80
100
0  0.01  0.1 1
0  0.1 1
Thapsigargin
0 5 10 15 20 25
60
80
100
 
ce
ll 
n
u
m
be
r 
( %
 )
 2.5 µM A23187
 serum deprivation
0 5 10 15 20 25
60
80
100
time (h)
ce
ll n
um
be
r 
( %
 )
 0.5 µM Thapsigargin
Tunicamycin
0.0 1 10
20
40
60
80
100
Brefeldin
Fig. 4. Eﬀect of ER-stressing reagents on cell integrity. (A) Various
concentrations of tunicamycin, brefeldin, A23187 or thapsigargin were
added to conﬂuent cells kept in medium containing 5% Hyclone calf
serum. The number of viable cells was determined after 24 h. ; AKR-
2B cells, j; MEF cells. (B) Time-dependent loss of viable cells. To
conﬂuent AKR-2B cells, the indicated amounts of A23187 or thapsi-
gargin, respectively, which evoked maximum loss of viable cells, were
added. For comparison, the kinetic of cell death induced by serum
starvation is included. After the indicated time intervals, the number of
viable cells was determined.3. Results
3.1. The expression of caspase-12 in AKR-2B cells is growth
regulated
The expression of caspase-12 was investigated by RT-PCR
and Western blotting (Fig. 1) RT-PCR showed a prominent
band of 1290 bp corresponding to the expected size of the
PCR-product and a minor band of about 1000 bp. Prolifer-
ating cells express only about 50% of both mRNA species of
caspase-12 compared to conﬂuent cells (Fig. 1A). As control,
the expression of the house keeping gene GAPDH was ana-
lyzed showing equal amounts of mRNA in both cases. Two
bands of 50- and 40-kDa, respectively, were detected by
Western blotting (Fig. 1B). A 50% decreased expression in
proliferating cells was also observed by Western blotting for
both the 50- and the 40-kDa bands. The expression of caspase-
12 was previously reported to be regulated during the devel-
opment in mouse embryos and was inducible by IFN-c in
mouse ﬁbrosarcoma and melanoma cells [17]. To investigate
the nature of the 1000-bp cDNA fragment and the corre-
sponding 40 kDa protein, the PCR products were cloned into
the Topo-vector (Invitrogen) and sequenced (Fig. 2). Indeed,
the 1290-bp insert codes for the full-length caspase-12. Inter-
estingly enough, the 1000-bp PCR product codes for a so far
unknown splice variant. Remarkably, almost the entire
CARD-domain is missing. The insert codes for a protein of
40.2 kDa (Fig. 2), which is in perfect agreement with the results
from Western blots. But surprisingly, the full-length sequence
of caspase-12 from AKR-2B cells contained three mutations
compared with the wild type obtained from the Marathon-
Ready cDNA library: I/L at position 15, E/D at position 46
and P/L at position 105. No mutation was found for caspase-
12 in MEF-cells (Fig. 2).
3.2. Diﬀerent subcellular localization of caspase-12 in AKR-2B
and MEF cells
Subcellular distribution was done by using the kit S-PEK
from Calbiochem, which is based on the diﬀerential solubility
of certain subcellular compartments in special reagent mix-
tures. Control proteins caspase-3, HtrA2 (omi), and Grp-78
showed the normal expected distribution, but for caspase-12
the distribution between cytosol and membrane/organelle
fraction was almost inverted between AKR-2B cells and MEF
(Fig. 3A). Whereas the major portion of caspase-12 wasmembrane/organelle-bound in MEF, for AKR-2B cells it was
predominantly found in the cytosol. These ﬁndings were sup-
ported by immunoﬂuorescence studies (Fig. 3B). AKR-2B cells
were transfected with the plasmid pECFP-ER to label specif-
ically the ER. For AKR-2B cells (Fig. 3B(a)–(c)), there was no
colocalization between ER-stain and immuno stain. To sub-
stantiate these ﬁndings, AKR-2B cells were transfected with a
wild-type HA-tagged caspase-12 construct. ER was stained
with the speciﬁc ER-tracker. Fig. 3B(d)–(f) shows a strong
overlap of transfected wild type caspase-12 with the ER, in-
dicative for an ER-localization of wild type caspase-12 in
AKR-2B cells.3.3. Activation without ER-stress
We have previously shown that in AKR-2B cells, fragmen-
tation and possibly activation of caspase-12 can be induced
either by serum starvation or by treatment with 10 lM an-
isomycin [25,26]. Concerning serum starvation, our results are
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cells, where no fragmentation of caspase-12 was observed after
serum deprivation [8].
We used various reagents known to induce ER-stress, to
tackle the question whether in AKR-2B cells the fragmentation
of caspase-12 is linked to ER-stress. Fig. 4 shows the eﬀect of
tunicamycin, brefeldin, ionophore A23187 or thapsigargin,
respectively, on the survival of AKR-2B cells. All reagents
were used over a wide concentration range covering those
concentrations applied in previous publications. Surprisingly,
neither tunicamycin nor brefeldin had any eﬀect on the number
of viable cells (Fig. 4A). Treatment with A23187 or thapsi-
gargin was ineﬀective after 6 h (data not shown) but led to a
cells loss of about 50% after 24 h (Fig. 4A). ED50-values were
0.4 lM for A23187 and 0.03 lM for thapsigargin, respectively.
Kinetic measurements for these two reagents were done at
concentrations eﬀecting maximum eﬃciency (2.5 lM for
A23187 or 0.5 lM for thapsigargin (Fig. 4B)). For compari-
son, kinetic data for serum starvation are included, which
show maximum cell death after 2.5 h. For A23187 and
thapsigargin much slower kinetics were observed. Remarkably,
there was no signiﬁcant cell death after 6 h, whereas at this
time point apoptosis induced by serum starvation was com-
plete. Thus, these data show that ER-stress- and serum de-
privation-induced cell death exhibit quite diﬀerentFig. 5. Eﬀects of ER-stressing reagents or serum starvation on the expression
cells were treated with (A) 1 lM tunicamycin or 3 lM brefeldin (B) 3 lMA23
without serum. Cells were lysed by treatment with cytobuster. Western blottin
3 were done as described in Section 2. * indicates cleavage products;  unc
Amido Black (47 kD protein).characteristics. Fig. 5 shows the eﬀect of ER-stressing reagents
in AKR-2B cells on the expression of Grp-78, an ER-speciﬁc
chaperone which is induced under ER-stress and on caspase-3
or -12. After treatment with brefeldin but not with tunicamy-
cin, there was a considerable loss of caspase-12 but no frag-
ments were detected. As expected there was a high increase in
Grp-78. Thus, both tunicamycin and brefeldin induced eﬀec-
tively ER-stress which is accompanied with an unspeciﬁc di-
gestion of caspase-12 in the case of brefeldin without any loss
of viable cells (Figs. 4A and 5A). There was no substantial loss
in the content of procaspase-3 induced by either of these re-
agents (shorter exposure times led to the same result (data not
shown)). Furthermore, the antibody against full-length cas-
pase-3 did not detect any fragments in the range of the large
subunit (19 kDa), though there were strong signals after serum
deprivation (Fig. 5), indicating that no major cleavage had
occurred. A23187 and thapsigargin behaved similar to brefel-
din regarding caspase-12 and Grp-78, but traces of a 19 kDa
cleavage product of caspase-3 could be detected. Remarkably,
serum starvation led to a substantial cleavage of caspase-12
(indicated by a star; Fig. 5C). Fragmentation of caspase-12
was maximum between 3 and 5 h, matching the kinetic data of
cell loss in Fig. 4. In parallel, there was a strong activation of
caspase-3 (Fig. 5C) [25]. Importantly, there was no increase in
Grp-78-expression.of Grp-78 and the cleavage of caspase-12 and -3. Conﬂuent AKR-2B
187 or 0.5 lM thapsigargin or (C) were starved in MCDB 402 medium
g and detection using antibodies against caspase-12, Grp-78 or caspase-
leaved caspases and , fragments of caspases. Control: staining with
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Fig. 6A shows a site by site comparison of caspase-12
fragments found in the cytosol of AKR-2B cells starved for 5
h, fragments generated by cleavage with caspase-3 in vitro in
cytosolic extracts from non-starved cells and in vitro translated
caspase-12 from AKR-2B cells. As markers, in vitro translated
caspase-12 fragments G95-end and T159-end were included.
Remarkably, in all instances a fragment comigrating with
caspase-12 G95-end (37 kDa) and a faint band with a molec-
ular weight of 48 kDa were observed. As shown in Fig. 6A, the
full-length caspase-12 from AKR-2B cells is largely degraded,
whereas the splice variant is less aﬀected. In lysates, caspase-3
eﬀectively digested the splice variant leading to an identical 37
kDa fragment (Fig. 6A), indicating that the cleavage site
DEED is still accessible. Our data suggest that the full-length
caspase-12 was more eﬃciently cleaved than the splice variant
during serum starvation. There was no indication for a
cleavage after K158, indicative for an action of calpain [7].
Only for in vitro translated caspase-12 treated with caspase-3,
there was a low molecular weight fragment of 28 kDa indic-
ative for an autoprocessing. In order to further assign the
diﬀerent fragments, caspase-12 and various mutants were ex-
pressed in vitro in an E. coli-based in vitro translation system.
The advantage of this system is the high protein yield and the
absence of endogenous caspases. Caspase-12 was detected by
Western blotting. Besides the expected 50-kDa band, a 31-kDa
species of variable intensity was seen in all experiments which
most likely represents a fragment of caspase generated by us-
ing a downstream methionine-169 as translation starter
(Fig. 6B). When in vitro synthesized caspase-12 was treated
with active caspase-3, three new bands were observed (48, 37
and 28 kDa). Mutation analysis by replacing D24 or D94 intoFig. 6. Comparison of in vivo and in vitro caspase-12 fragmentation.
(A) Lysates from non-starved cells (N) and from cells starved for 5 h
(S) were separated on 12% SDS–polyacrylamide gels. If indicated (+),
recombinant caspase-3 was added. For comparison, full-length cas-
pase-12 (F), caspase-12 G95-end (G) or caspase-12 T159-end (T) was
translated in vitro and, if indicated (+), treated with caspase-3. The 40-
kDa band indicated by a star is the caspase-12 splice variant. (B) The
cDNA coding for caspase-12 was cloned into the pET-3d or pET-21b
vector, respectively, starting with a methionine. No tags were added.
Mutated residues are indicated. The addition of recombinant caspase-3
is indicated by a +. Aliquots of about 3 lg of protein were subjected to
SDS gel electrophoresis using a 12% gel. , uncleaved caspase-12 and
, fragments of caspase-12.alanine identiﬁed D94 and D24 as cleavage sites for caspase-3
(Fig. 6B). In the mutant D94A, the fragment of 28 kDa was
missing, suggesting that this fragment was generated by au-
tocleavage of caspase-12. Therefore, a mutant C298A was
generated. After treatment of the mutant protein with caspase-
3, the 28-kDa band almost disappeared, indicating a pre-
dominant autocleavage. Importantly, in the mutant D94A
caspase-3 treatment led only to a cleavage at D24 (48 kDa)
without the generation of the 28-kDa fragment. Thus, for
autoprocessing the removal of the entire N-terminal CARD-
domain up to D94 appears to be necessary. Mutation analyses
in the linker region between the large an the small subunit
(D318A/D320A and D341A) revealed that D341 was the tar-
get for autocleavage. These data suggest that caspase-12 was
indeed cleaved at D24 and D94 by caspase-3 in vivo in AKR-
2B cells.4. Discussion
Caspase-12 from AKR-2B cells contains three point muta-
tions compared with the wild type (Fig. 2). As a consequence, a
signiﬁcant part of caspase-12 is localized in the cytoplasma.
There was no indication for an attachment to the ER and ER
stress induced by tunicamycin, thapsigargin, brefeldin and
A23187 did not lead to a cleavage of caspase-12 in AKR-2B
cells. In contrast, as shown previously, serum deprivation or
anisomycin treatment induced cleavage of caspase-12 [25,26]
and importantly, this cleavage paralleled the kinetic of apop-
tosis and caspase-3 activation (Figs. 4 and 5). During these
both types of treatment the ER was not stressed, since there
was no increase in the protein content of Grp-78 and the
[Ca2þ] homeostasis was not aﬀected [26]. An obvious reason
for this discrepancy is the binding of caspase-12 to high mo-
lecular weight complexes located in the cytosol, ﬁrst described
by our group, in AKR-2B cells. Similar to activation involving
the ER, caspase-12 is released from this complex and low
molecular weight fragments are recovered after gel chroma-
tography in the region corresponding to a heterotetrameric
protein [25,26]. The analysis of cleavage sites indicates a pro-
cessing by caspase-3 (Fig. 6) which is the main executioner
caspase in AKR-2B cells, since caspase-7 is not detectable in
these cells [25]. Possibly, caspase-3 action leads to a displace-
ment of caspase-12 from the high molecular weight complex,
which is not consistent with a role of caspase-12 as an initiator
for caspase-3. Also, the fact that caspase-3 and-12 are cleaved
at the same time point does not favor a role as initiator cas-
pase. On the contrary, in AKR-2B cells caspase-12 seems to be
downstream of caspase-3 since in starved cells caspase-12 is
apparently cleaved at postion D-94, which is the cleavage site
for caspase-3. But on the other hand, there was no further
processing in the intersubunit region leading to fragments 28
kDa, though in vitro translated caspase-12 was able to auto-
process at D-341 after cleavage at D-94 by caspase-3. One
explanation is the much higher concentration of caspase-12 in
the in vitro translation assay. It has been proposed, based on in
vitro and in vivo data, that caspase-12 initiates a caspase
cascade by cleaving caspase-9 which then cleaves caspase-3
[9,18]. This pathway induced by ER-stress seems to be largely
excluded in AKR-2B cells, since we did not observe cleavage of
caspase-9 during apoptosis induced either by serum starvation
or by treatment with anisomycin nor a recruitment into ap-
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activation of caspase-3, which does not require the formation
of an apaf-1/caspase-9/cyt c complex [25,26]. Interestingly, the
existence of this pathway has been conﬁrmed recently by using
apaf-1= and caspase-9= cell lines [31]. But so far, AKR-2B
cells are the only example where such a pathway is utilized
though both apaf-1 and caspase-9 are present in the cell.
AKR mice show a high incidence for the development of
leukemia [32–35]. Although this phenomenon has been at-
tributed to the spontaneous expression of murine leukemia
virus in these mice [36]], the altered location of caspase-12
described here may also contribute to the establishment of the
above mentioned phenotype. AKR mice thus may serve as a
mouse model to test the involvement of caspase-12 in various
diseases. Interestingly enough, like in knockout mice [8] the
eﬀect of a diﬀerent location of caspase-12 in AKR-2B cells was
not lethal for the respective animals.
The nucleotide sequences are deposited under the number
AY675224 for full-length caspase-12 and AY675223 for the
splice variant from AKR-2B ﬁbroblasts.
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